InVivoMAb抗小鼠NK1.1/InVivoMAb anti-mouse NK1.1方案

PK136单克隆抗体与小鼠NK1.1（也称为CD161b/CD161c、KLRB1、NKR-P1A和Ly-55）反应。NK1.1是一种具有C型凝集素结构域的II型整合膜糖蛋白，由Klrb1c/NKR-P1C基因编码。NK1.1在NK细胞活化和分化、IFN-γ产生、细胞毒性颗粒释放中起作用，并被认为参与Th2细胞的产生。NK1.1主要在NK细胞上表达为二硫键连接的同二聚体，然而，它也在NK-T细胞上表达，这是一种罕见的T淋巴细胞群。NK 1.1仅由C57BL/6、FVB/N和NZB小鼠品系表达，不表达AKR、BALB/c、CBA/J、C3H、DBA/1、DBA/2、NOD、SJL和129品系。

艾美捷InVivoMAb抗小鼠NK1.1/InVivoMAb anti-mouse NK1.1：

货号：BXC-BE0036

亚型：小鼠IgG2a，κ

推荐同种型对照：InVivoMAb小鼠IgG2a同种型对照，未知特异性

推荐稀释液：InVivoPure pH 7.0稀释液

偶联：未偶联。提供抗体偶联服务。

免疫原：小鼠脾脏和骨髓细胞，富含NK1+细胞

报告应用：体内NK细胞耗竭、流式细胞术

配方：PBS，pH 7.0

不含稳定剂或防腐剂

内毒素：<2EU/毫克（<0.002EU/微克）

由LAL凝胶凝固测定法确定

纯度：>95%

由SDS-PAGE确定

无菌性：0.2微米过滤

在无动物设施中从细胞培养上清液中纯化

纯化：蛋白质A

分子量：150 kDa

储存：抗体溶液应以原始浓度在4°C下储存。不要冷冻。

InVivoMAb抗小鼠NK1.1/InVivoMAb anti-mouse NK1.1文献参考：

in vivo NK cell depletion

Glasner, A., et al. (2018). "NKp46 Receptor-Mediated Interferon-gamma Production by Natural Killer Cells Increases Fibronectin 1 to Alter Tumor Architecture and Control Metastasis" Immunity 48(1): 107-119 e104.

in vivo NK cell depletion

Burrack, K. S., et al. (2018). "Interleukin-15 Complex Treatment Protects Mice from Cerebral Malaria by Inducing Interleukin-10-Producing Natural Killer Cells" Immunity 48(4): 760-772 e764.

in vivo NK cell depletion

Moynihan, K. D., et al. (2016). "Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses" Nat Med. doi : 10.1038/nm.4200.

in vivo NK cell depletion, Flow Cytometry

Ludigs, K., et al. (2016). "NLRC5 shields T lymphocytes from NK-cell-mediated elimination under inflammatory conditions" Nat Commun 7: 10554.

in vivo NK cell depletion

Ghasemi, R., et al. (2016). "Selective targeting of IL-2 to NKG2D bearing cells for improved immunotherapy" Nat Commun 7: 12878.